Overview

Study to Evaluate the Safety and Efficacy of CJ-30060 in Hypertensive Patients With Hyperlipidemia

Status:
Completed
Trial end date:
2017-09-04
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of CJ-30060 compared with amlodipine/valsartan combination therapy and valsartan/rosuvastatin combination therapy in hypertensive patients with hyperlipidemia
Phase:
Phase 3
Details
Lead Sponsor:
CJ HealthCare Corporation
HK inno.N Corporation
Treatments:
Amlodipine
Rosuvastatin Calcium
Valsartan